Last news analysis

M&A: is a new shopping spree likely in 2021?

By The Editor - 20 January 2021

Unlike previous years, the 39th J.P. Morgan Healthcare Conference was not held in San Francisco, but took place virtually through video conferencing. Between the closing of the 2020 J.P. Morgan Healthcare conference and January 2021, the pharmaceutical industry had to face a global pandemic. But in spite of lockdowns, social distancing restrictions, economic breakdown, the pharma industry recorded an amazing 2020 year in terms of acquisitions and partnerships..


2020 European approvals in good health

By The Editor - 13 January 2021

Year-to-date tally at the European Medicines Agency (EMA) suggests the trend for new drug approvals in 2020 hasn't suffered from the Covid-19 pandemic. At the end of the 11 Committee for Medicinal Products for Human Use (CHMP) meetings, some 96 new medicines were approved in Europe throughout the year.


2020 FDA approvals: close to a new record

By The Editor - 07 January 2021

As Commissioner Stephen Hahn will depart the FDA by January 20, when the Biden administration takes office, review of drug approvals in 2020 shows the Covid-19 pandemic did not slow the trend. According to the FDA, the Center for Drug Evaluation and Research approved 53 "first-of-their-kind medicines" for the US market....


a new and profitable arena with Alexion?

By The Editor - 15 December 2020

AstraZeneca's $39 billion acquisition of Alexion strengthens several assumptions: firstly, rare-disease segment is more and more becoming a key issue for big and small pharmaceutical companies; secondly mega-deals are not over (it is the largest deal in AstraZeneca's history). And thirdly, there is still future for the pharmaceutical industry outside Covid-19 R&D.


EQT IX announces a public offer
to the shareholders of Recipharm AB

By The Editor - 14 December 2020

EQT IX, through Roar BidCo AB, announced a public offering of SEK 220 in cash per share to the shareholders of Recipharm AB and SEK 1,427,010 per Recipharm convertible bond with a par value of 1 000,000 SEK.


Is it time for the return of gene therapy?

By The Editor - 10 December 2020

The R&D on Covid-19 vaccines and treatments is not the only goal of Big Pharma. Interest in gene therapy development remains very high, as evidenced by several recent deals and agreements.


Without european CDMOs' no vaccines!

By The Editor - 9 December 2020

European CDMOs are becoming essential players in producing the hundreds of millions of doses of anti-Covid-19 vaccines.

Curevac NV and Fareva today announced their agreement for the Fill & Finish manufacture of CVnCoV, CureVac's COVID-19 vaccine candidate.


Covid-19 R&D: what else besides vaccines?

By The Editor - 3 December 2020

While Pfizer/BioNTech's Covid-19 vaccine candidate gained emergency use authorization in the UK on December 2, making it the first in Europe to get the green light, what happened in the rest of the pharma-industry? Many things for sure, as all companies are not exclusively working on vaccines.


AstraZeneca-Oxford's vaccine:
still a good candidate?

By The Editor - Created 25 November 2020 - Updated 2 December 2020

AstraZeneca and the University of Oxford are likely to conduct a further global study of their Covid-19 vaccine candidate AZD1222, which would evaluate an initial low-dose of the vaccine...


Covid-19 Vaccines:
The Exceptional Logistics Challenge

By The Editor - 27 November 2020

Humanity is faced with an unprecedented vaccination effort in order to achieve collective immunity close to 70%, or 5.5 billion people worldwide! Over 10 billion doses will need to be produced over time! Either by optimizing at best, in sterile vials of 10 doses, this represents a billion vials to be filled, packaged, stored, and sent to the places where the vaccine doses are distributed.


The ApiJect Gigafactory, featuring the world's largest pharmaceutical fill-finish facility

By The Editor - 23 November 2020

ApiJect Systems, Corp., has been approved by the U.S. International Development Finance Corporation (DFC) for a $590 million loan to construct a multi-facility campus enabling the U.S. to more quickly package high volumes of injectable medicines and vaccines...


Amazon attacks the US pharmacy market

By The Editor - 23 November 2020

American pharmacies and drugstore chains have a formidable new competitor: Amazon. The giants of the sector, CVS, Walgreens and RiteAid, but also the pharmacies of large low-cost distribution, such as Walmart and Costco, have been expecting for months such an official announcement, likely to upset the market of 300 billion dollars from the sale of drugs in the United States....


Pfizer vs Moderna
competition and race speed up

By The Editor - Created 20 november 2020 - Updated 25 november 2020

The path is gradually clearing for laboratories battling against Covid-19. And the race to bring a vaccine to the market has dramatically sped up during the past weeks with several announcements by Pfizer and Moderna....


Deals between drugmakers and CDMO
on Covid-19 accelerate

By The Editor - 19 November 2020

While the giants of drug and biotechnology manufacturers are working in a frantic race on the projects of vaccine candidates, many manufacturing contracts are under negotiation in order to meet the production capacities to be implemented.


Building the European Health Union

By The Editor - 18 November 2020

The European Health Union is on track; mid-November European Commission president, Ursula von der Leyen offered a €5 billion budget dedicated to health over the next seven years...


The "ups and downs" of Alzheimer's R&D

By The Editor - 12 November 2020

Will aducanumab become one day the first medication approved for Alzheimer? What happened last week confirms if needed that the story has not been written yet and that the cycle failure is not over...


Top 10 blockbusters' resilience in 2020

By The Editor - 5 November 2020

Were the Top 10 best-selling pharmaceutical drugs in the world impacted by social distancing measures, delays in elective surgeries, prioritization of Covid-19 patients during the first nine months of 2020? As most drugmakers have just announced their third quarter results, it is clear that Big Pharma's resilience is a reality, while blockbusters still make their way...




Pfizer's Covid-19 vaccine candidate:
what are the next steps?

By The Editor - 10 November 2020

Results from the first interim analysis of a Phase III study of Pfizer and BioNTech's BNT162b2 have raised huge enthusiasm all over the world as the pandemic is speeding up, forcing governments to enact new lockdowns. ...


The pandemic accelerates so are trials
on Covid-19 treatments

By The Editor - 27 October 2020

While the Covid-19 pandemic shows no sign of decrease and accelerates on the contrary dramatically in many parts of the world, urging governments to set up more restrictive measures, several drugmanufacturers raise hopes for potential coronavirus vaccines or treatments in the coming weeks or months.


China's "whatever it costs" plan
against Covid-19

By The Editor - 14 October 2020

The country is becoming more and more a worldwide turntable for R&D and trials against the pandemic.


Moderna scrutinizes the end of the year

By The Editor - 21 October 2020

As the Covid-19 pandemic is swelling, R&D drugmakers' efforts to find a vaccine candidate are closely scrutinized. Moderna is on track to score an emergency use authorization (EUA) in December


J&J, AstraZeneca: the risk of "temporarily pause" in clinical trials

By The Editor - Created 06/10/20 - Updated 14/10/20

A new hurdle occurred in the race to bring a vaccine candidate against Covid-19 to the market


Pfizer's goals: battling the Covid-19
and adding $15 billion sales

By The Editor - 24 september 2020

While growing anxiety is spreading worldwide with sanitary indicators on the evolution of the Covid-19 pandemic getting worse, impatience for a vaccine to arrive is growing


How governments secure future vaccines
for their citizens

By The Editor - 03 september 2020

In the race against Covid-19, drug companies are speeding to bring to market a vaccine. Meanwhile, for months, governments from all around the world have been working on supply deals to secure millions of doses of the future vaccines candidates for their citizens.

From our correspondent Washington


Purdue Pharma pleads guilty in opioid scandal

12 November 2020

As isolation and depression, compounded by the COVID-19 pandemic, have caused opioid overdose deaths in the United States to soar to over 450,000, the laboratory most implicated in the catastrophe, Purdue Pharma, has just reached a settlement with the Department of Justice...

FINANCIAL: News & Stock

Covid-19 pandemic weakens financial results

By The Editor - 5 august 2020

The pandemic and the economic lockdown severely reduced prescriptions for medicines, doctors or hospitals visits by patients and also delayed uses of innovative treatments. With immediate financial consequences on companies' sales and revenues.


FAREVA strengthens in the production of injectable forms with high added value

By The Editor - 23 October 2020

Fareva enters into exclusive negotiations with Novartis to take over the production site in Unterach (Upper Austria), recognized as the center of excellence for the manufacture of injectable cancer drugs.


Bristol-Myers-Squibb's come back
in cardiovascular

By The Editor - 8 october 2020

Who's next to catch the big pharma deal train? Definitely Bristol-Myers-Squibb is. On October 5th, the American company penned its second large deal in two years, with the acquisition of biotech firm MyoKardia Inc., specialized in cardiovascular, for $13.1 billion...


Big Pharma speed up on acquisitions
in rare diseases and cancer

By The Editor - 16 september 2020

If the first half of 2020 has not been a busy time for acquisitions, things have definitely changed in the second half so far, with several announcements happening at the end of August and in September


Browse editions

Go to Top